Milestone Scientific Inc Dossier - Source-backed chat

Milestone Scientific Inc

MLSSNYSE

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.01

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $0.41Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $37.1M

Enterprise Value $36.7M

Shares Outstanding 87.5M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Milestone Scientific is transitioning from a period of restructuring to commercial execution under new leadership. By implementing strict cost discipline, launching targeted commercial programs (such as the Dental Ambassador and CompuFlo Advisor programs), and securing key Medicare reimbursement milestones, the company is positioning itself to achieve cash flow breakeven in early 2027. While balance sheet constraints and listing compliance risks remain, the recent $2.15 million private placement provides the necessary runway to scale high-margin medical and dental adoption.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$1.25

High · most bullish analyst$1.50

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.2015%

Slow clinical adoption of CompuFlo due to reimbursement friction or delayed procurement cycles. International dental sales remain soft, and cash burn accelerates, forcing highly dilutive equity raises or risking delisting from the NYSE American if stockholders' equity remains below thresholds by April 2027.

Base CaseCentral scenario

$1.0060%

Milestone achieves its reaffirmed 2026 revenue guidance of $9.8 million to $10.2 million, supported by a 400% increase in CompuFlo sales to $500,000–$600,000. Operating losses continue to narrow due to structural cost reductions, and the company remains on track to reach cash flow breakeven in early 2027, successfully resolving its NYSE American listing compliance issues.

Bull CaseUpside scenario

$1.5025%

Rapid commercial adoption of the CompuFlo Epidural System driven by successful execution of the Advisor Program and transition of CPT code 0777T to Category I. Dental Ambassador program scales nationally, and international registrations in Japan, India, and Mexico open high-growth markets, leading to revenue exceeding the high end of 2026 guidance.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary Dynamic Pressure Sensing (DPS) technology provides objective, real-time feedback, reducing epidural complication rates by 91% according to peer-reviewed research.
Reaffirmed double-digit revenue growth guidance for 2026 ($9.8M–$10.2M) with CompuFlo sales projected to grow ~400% year-over-year.
Strong operational turnaround under CEO Eric Hines, reducing Q1 2026 operating expenses by over 30% and narrowing net losses significantly.
Established reimbursement pathway with Medicare Part B physician payment rates granted in key jurisdictions under CPT code 0777T.

Key Investment Risks

Going concern uncertainty highlighted by an accumulated deficit of approximately $134.6 million and limited cash reserves.
NYSE American non-compliance risk due to stockholders' equity falling below the required $4.0 million and $6.0 million thresholds.
Potential dilution from outstanding warrants, convertible notes, and the April 2026 private placement of 7.96 million units.
Geopolitical and supply chain disruptions, such as Middle East conflicts delaying booked dental shipments.

Thesis Invalidation Triggers

Failure to achieve cash flow breakeven by early 2027.
Delisting from the NYSE American due to failure to regain compliance with stockholders' equity requirements by April 2027.
Inability to transition CPT code 0777T from Category III to Category I due to low case submission volumes.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.